The stock of Pacira BioSciences Inc (NASDAQ:PCRX) last traded at $12.40, up 0.90% from the previous session.
PCRX stock price is now -48.01% away from the 50-day moving average and -55.93% away from the 200-day moving average. The market capitalization of the company currently stands at $572.01M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $30 to $8, Truist Downgraded its rating from Buy to Sell for Pacira BioSciences Inc (NASDAQ: PCRX). On August 12, 2024, RBC Capital Mkts Downgraded its previous ‘Outperform’ rating to ‘Sector Perform’ on the stock reducing its target price from $37 to quote $14, while ‘Raymond James’ rates the stock as ‘Mkt Perform’
In other news, Lee Frank D., Chief Executive Officer bought 8,264 shares of the company’s stock on Aug 12 ’24. The stock was bought for $99,994 at an average price of $12.10. Upon completion of the transaction, the Chief Executive Officer now directly owns 107,784 shares in the company, valued at $1.34 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 12 ’24, Director BIGAL MARCELO bought 3,400 shares of the business’s stock. A total of $40,834 was incurred on buying the stock at an average price of $12.01. This leaves the insider owning 8,630 shares of the company worth $0.11 million. A total of 3.02% of the company’s stock is owned by insiders.
During the past 12 months, Pacira BioSciences Inc has had a low of $11.26 and a high of $38.23. As of last week, the company has a debt-to-equity ratio of 0.74, a current ratio of 6.82, and a quick ratio of 5.70. According to the stock market information, the enterprise value for the company is $816343104, which is based on a 9.64 price-to-earnings ratio, a 0.89 price-to-earnings-growth ratio, and a beta of 0.96. The fifty day moving average price for PCRX is $23.4902 and a two-hundred day moving average price translates $28.06075 for the stock.
The latest earnings results from Pacira BioSciences Inc (NASDAQ: PCRX) was released for 2024-06-30. The net profit margin was 9.21% and return on equity was 7.54% for PCRX. The company reported revenue of $178.02 million for the quarter, compared to $169.47 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.05 percent.
